Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance
Open Access
- 22 April 2020
- journal article
- review article
- Published by Elsevier BV in New Microbes and New Infections
- Vol. 35, 100684
- https://doi.org/10.1016/j.nmni.2020.100684
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 2020
- Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitroCell Discovery, 2020
- In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clinical Infectious Diseases, 2020
- Inhibitors of nuclear transportCurrent Opinion in Cell Biology, 2019
- Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP importScientific Reports, 2016
- Evaluation of cytotoxicity and antiviral activity of ivermectin against Newcastle disease virus.2015
- 25Cytokine, 2014
- Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replicationAntiviral Research, 2013
- Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drugJournal of Antimicrobial Chemotherapy, 2012
- Mechanism of action of hydroxychloroquine as an antirheumatic drugSeminars in Arthritis and Rheumatism, 1993